Methadone and buprenorphine for the management of opioid dependence

TA114 Drug misuse - methadone and buprenorphine: review decision - November 2010 information

Appendix A: decision paper considered by the Institute's Guidance Executive (PDF 70 KB)

Drug misuse - methadone and buprenorphine: Review Proposal - August 2010 information

Appendix A: provisional matrix of stakeholders (PDF 32 KB)

Appendix B: proposal paper presented to the Institute's Guidance Executive (PDF 150 KB)

Drug misuse - methadone and buprenorphine: Final appraisal determination information

Drug misuse - methadone and buprenorphine: Final appraisal determination document (PDF 104 KB)

Drug misuse - methadone and buprenorphine: Response to consultee and commentator comments on the ACD (PDF 98 KB)

Drug misuse - methadone and buprenorphine: Appraisal consultation document information

Drug misuse - methadone and buprenorphine: Evaluation report

Overview (PDF 185 KB)

Assessment report (PDF 1.35 MB)

Drug misuse - methadone and buprenorphine: Final scope (PDF 30 KB)

Drug misuse - methadone and buprenorphine: Final protocol (PDF 100 KB)

Drug misuse - methadone and buprenorphine, comments on provisional matrix (PDF 13 KB)

Drug misuse - methadone and buprenorphine, comments on draft scope (PDF 41 KB)

Drug misuse - methadone and buprenorphine: Draft scope (PDF 28 KB)

Drug misuse - methadone and buprenorphine: Provisional matrix of consultees and commentators (PDF 29 KB)

2004/027 NICE asked to develop guidance on the care of drug misuse, medicines for prostate cancer, and management of attention deficit hyperactivity disorder information